Peter J. O'Dwyer, MD
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Penn Medicine Provider
About me
- Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
My education and training
- Residency: Saint Patrick's Hospital and Health Sciences Center
- Residency: Hammersmith Hospital
- Residency: Waterbury Hospital
- Residency: Greater Baltimore Medical Center
- Fellowship: University of Maryland Medical Center
- Fellowship: National Cancer Institute
Spoken languages
English
English
Reviews
78 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Qualifications and experience
- Medical Oncology, 1987
- Pediatrics, 1983
- Internal Medicine, 1981
- 11th NCI/EORTC/AACR Symposium on New Drugs in Cancer Therapy,
- 2nd International Workshop on Targeted Therapy in Colorectal Cancer,
- 3rd International Pharmacodynamics Workshop, Tidewater, Virginia,
- 7th International Meeting on Chemical Modifiers of Cancer Treatment,
- Adjuvant Colon Studies, NSABP,
- American Association for Cancer Research,
- American Association for the Advancement of Science,
- American Cancer Society,
- American College of Physicians,
- American Federation Clinical Research,
- American Society of Clinical Oncology,
- American Society of Clinical Pharmacology and Therapeutics,
- American Society of Hematology,
- American Society of Preventive Oncology,
- Center for Biomedical Continuing Education,
- Center for Biomedical Continuing Education,
- College of Physicians Philadelphia,
- Colon Cancer Alliance,
- Eastern Cooperative Oncology Group,
- EORTC 1st Translational Research Symposium, Brussels,
- EORTC Protocol Review Committee,
- Festschrift for Dr. Patrick Creaven, Buffalo,
- Gastrointestinal Cancer, International Congress of Chemotherapy,
- International Meta-Analysis Group in Cancer,
- International Workshop on Targeted Therapy in Colorectal Cancer,
- National Cancer Institute,
- New Agents/Pharmacology, CALGB,
- Pennsylvania Oncology Society,
- Pharmacokinetics and Metabolism Group, EORTC,
- SPORE in pancreatic cancer, NYU,
- Summit on Clinical Trials, Washington, DC,
- Summit V, Workgroup on Trial Design,
- U.S.-Japan Cancer Research Symposium, Tokyo,
- Working Group on ECOG/EORTC Coordination,
- Penn Gastrointestinal Cancer Program
Treatments and conditions
Research
Publications
Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL Comparison between the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur plus oral leucovorin regimen in Japanese and American patients with advanced colorectal cancer: joint USA and Japan study of UFT/LV , : 2003
Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy , Cancer Chemother Pharmacol: 2003
Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors , : 2003
Yao KS, O’Dwyer PJ Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention , Biochem Pharmacol: 2003
Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI Gene expression patterns in epithelial ovarian carcinomas , : 2003
Flaherty KT, O'Dwyer PJ Phase II trials in oncology , Anticancer Drug Development Guide: 2003
Vasilevskaya I, O’Dwyer PJ Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy , Drug Resistance Updates: 2003
O’Dwyer PJ, Johnson SW Current status of oxaliplatin in colorectal cancer , Semin Oncol, 30(3 Supp 6): 2003,78-87
Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies , : 2003
Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer , : 2003